Difference between revisions of "TRK fusions"

From Libre Pathology
Jump to navigation Jump to search
(create)
 
Line 12: Line 12:
 
==Association==
 
==Association==
 
*MASC.
 
*MASC.
*Secretory breast carcinoma.
+
*Secretory breast carcinoma - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal  | last1 = Vasudev | first1 = P. | last2 = Onuma | first2 = K. | title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. | journal = Arch Pathol Lab Med | volume = 135 | issue = 12 | pages = 1606-10 | month = Dec | year = 2011 | doi = 10.5858/arpa.2010-0351-RS | PMID = 22129193 }}</ref>
  
 
==Drugs==
 
==Drugs==

Revision as of 01:41, 11 September 2018

TRK fusions are seen in many solid tumours and have targeted drugs.

Genes:

  • TRK1
  • TRK2
  • TRK3

The TRK genes are tyrosine kinase receptors.

Multiple fusion partners for each gene.

Association

  • MASC.
  • Secretory breast carcinoma - ETV6-NTRK3.[1]

Drugs

  • Merestinib.
  • Larotrectinib.
  • Others.

See also

References

  1. Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.